Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 699

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 699
---
 Twito             |
| Title:                          |     | Chief Executive Officer |

Annex A-82 Annex B Execution Version Form of NLS Support Agreement VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “ Agreement ”), dated as of ________________, 2024 (the “ Effective Date ”), by and among NLS Pharmaceutics Ltd. (the “ Company ”), a corporation incorporated under the laws of Switzerland, and certain the shareholders of the Company listed on Schedule A hereto (each, a “ Shareholder ” and, collectively, the “ Shareholders ”). RECITALS WHEREAS, concurrently herewith, the Company, NLS Pharmaceutics Ltd., an Israeli company and a wholly owned subsidiary of the Company (“ Merger Sub ”), and Kadimastem Ltd., an Israeli publicly traded company (“ Kadimastem ”), are entering into an Agreement and Plan of Merger (the “ Merger Agreement ”; capitalized terms used but not defined in this Agreement shall have the meanings ascribed to them in the Merger Agreement), pursuant to which (and subject to the terms and conditions set forth therein) the Company, Kadimastem, and Merger Sub intend to effect a merger of Merger Sub with and into Kadimastem (the “ Merger ”), whereupon consummation of the Merger, the separate corporate existence of Merger Sub shall cease and Kadimastem shall continue as the surviving company and a wholly owned subsidiary of the Company; WHEREAS, pursuant to the Merger Agreement, the Company has agreed to hold the Parent Shareholder Meeting for the purpose of approving (i) the issuance of shares of common stock, par value 0.08 Swiss Franc (CHF) per share, of the Company (“ Common Stock ”), equal to the required number of shares of Common Stock to serve as the Merger Consideration (all references to numbers of shares of Common Stock, and the par value of the Common Stock, shall be appropriately adjusted to reflect any share dividend, split, combination, or other recapitalization affecting the Common Stock occurring after the Signing Date), and (ii) an ordinary capital increase under Swiss law, excluding the subscription rights of the existing Company shareholders, for the purpose of making available the required number of shares of Common Stock to serve as the Merger Consideration ((i) and (ii) collectively, the “ Shareholder Resolutions ”); WHEREAS, each Shareholder is the record or “beneficial owner” (within